Express News | Raymond James Initiates Coverage On Sernova With Market Perform Rating, Announces Price Target of $1.5

Moomoo 24/7Apr 4 13:49 ET

Sernova Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 277.41% Raymond James → $1.5 Initiates Coverage On → Market Perform

BenzingaApr 4 13:47 ET

Sernova Reports Anticipated 2024 Milestones

Seeking AlphaJan 29 07:21 ET

Sernova Gets FDA Orphan Drug, Rare Pediatric Designations for Hemophilia A

Seeking AlphaNov 27, 2023 15:06 ET

Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for Its Hemophilia A Program From FDA

LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S.

GlobeNewswireNov 27, 2023 07:19 ET

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years;5 of 6 patients in Cohort A

GlobeNewswireOct 27, 2023 07:00 ET